Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new trial, adding to growing threats to the Danish company’s early dominance in the surging market for new weight-loss treatments.

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.